In another study, Bellavia et al. engineered HEK293T cells to display the LAMP-2B fused with Interleukin 3 (IL3) segment, and collected the IL3-LAMP-2B exosomes to load with Imatinib or with BCR-ABL siRNA, targeting CML cells and inhibiting cancer progression in vitro and in vivo[52]. This evidence concerns the gene IL3 and chronic myelogenous leukemia, BCR-ABL1 positive.